In patients with relapsed or metastatic SCLC who received pembrolizumab monotherapy (regardless of PD-L1 expression), the ORR was 18.7%, median OS was 8.7 months, and median PFS was 2.0 months. The gene discussed is CD274; the disease is small cell lung carcinoma.